JAK2 and myeloproliferative neoplasm: To compare these diversities, we combined extensive gene expression and proteomic profiling in CD34+ cells and granulocytes from JAK2 mutation positive MPN (PV, ET and PMF) and JAK2 negative MPN (ET and PMF) subjects.